Therapeutic Effects of Zoledronic Acid-Loaded Hyaluronic Acid/Polyethylene Glycol/Nano-Hydroxyapatite Nanoparticles on Osteosarcoma
Zoledronic acid (ZOL) has been approved as the only bisphosphonate for the prevention and treatment of metastatic bone diseases with acceptable safety and tolerability. However, systemic or direct injection of ZOL often causes severe side effects, which limits its clinical application. Here, an inno...
Saved in:
| Main Authors: | Yan Xu, Jingqi Qi, Wei Sun, Wu Zhong, Hongwei Wu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fbioe.2022.897641/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case Report: Acute Unilateral Uveitis Induced by Infusion of Zoledronic Acid
by: Kadir Songür, et al.
Published: (2022-08-01) -
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
by: Roberta Scafetta, et al.
Published: (2025-08-01) -
Green analytical chemistry and quality by design: A combined approach towards simultaneous determination of Letrozole with its co-administered Zoledronic Acid for cancer patients
by: Nourhan A. Abd El-Fatah, et al.
Published: (2024-12-01) -
Systemic strategies for osteosarcoma: advances and future directions
by: Vivek Kumar Morya, et al.
Published: (2025-07-01) -
SIRPA, BTN3A1, and TDO2 in osteosarcoma: a prognostic triad with therapeutic implications from integrated genomic and pharmacogenomic data
by: Han-jing Zhang, et al.
Published: (2025-08-01)